National Institute for Health and Clinical Excellence (NICE)
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body
The positive recommendation follows consultation on NICE’s previous draft guidance which did not recommend atezolizumab. The company has agreed to provide a larger discount to the list price of the drug following a deal with NHS England & NHS Improvement.
Around 2000 people in England have triple negative breast cancer, of whom around 600 people would be eligible for treatment with atezolizumab and nab-paclitaxel.
Given by injection every 2 weeks with chemotherapy drug nab-paclitaxel, atezolizumab (also called Tecentriq and made by Roche) works by blocking the activity of a protein called PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person’s own immune cells to attack the cancer.
Atezolizumab is the first immunotherapy that specifically targets triple negative breast cancer where tumours have PD-L1 expression of 1% or more. It is given to people who have not had chemotherapy for breast cancer that has spread to other parts of the body and where surgery to remove it is not possible.
The evidence suggests that atezolizumab plus nab-paclitaxel increases the time before the disease worsens by around 2.5 months. It also suggests that atezolizumab plus nab-paclitaxel can increase overall survival by around 9.5 months.
Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE, said: “We are pleased to have been able to work with the company to resolve the issues identified by the committee in our previous draft guidance. I know that today’s announcement will be welcomed by people with this type of breast cancer as well as for their families and carers. Atezolizumab is considered to be a breakthrough treatment in an area where there are currently few options.
“The committee heard that the availability of a new treatment that increases progression-free survival compared with chemotherapy alone will give hope to patients because it is important to them to be able to maintain a good quality life for as long as possible.”
Professor Peter Johnson, NHS clinical director for cancer said: “As well as ensuring the safety of cancer patients during the pandemic, the NHS is also working hard to make sure that the best care and treatment options are available for them.
“We are delighted that we were able to strike a deal with the company to support NICE’s recommendation for atezolizumab, which will help hundreds of people with breast cancer and their families – it means that patients with triple breast cancer have a significantly better option for treatment.”
Advanced triple negative breast cancer has a significant negative impact on the quality of life of patients. It can be more aggressive than other types of breast cancer (despite accounting for only 15–20% of breast cancer cases, it accounts for 25% of deaths). The committee heard from the patient expert that the burden of the disease on the family is high, both emotionally and financially.
The cost of a course of treatment with atezolizumab is £39,981 based on treatment for 7.5 months at its full list price but the company offered the NHS a confidential discount.
NICE expects to publish its final guidance on atezolizumab for triple negative breast cancer in June 2020.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Commonly used treatments for chronic pain can do more harm than good and should not be used, says NICE in draft guidance04/08/2020 11:15:00
A number of commonly used drug treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE said in its draft clinical guideline published yesterday (3 August 2020) on the assessment and management of chronic pain in over 16s.
New combination treatment for patients with advanced kidney cancer31/07/2020 13:10:00
Adults with advanced renal cell carcinoma can now be offered avelumab with axitinib as a first line treatment option on the Cancer Drugs Fund (CDF), NICE has said in final draft guidance.
NICE publishes new COVID-19 rapid guideline on arranging planned care in hospitals and diagnostic services28/07/2020 09:15:00
NICE yesterday (27 July 2020) published a guideline on the arrangements the NHS should put in place for patients needing elective surgery and other planned treatments and procedures (including diagnostics and imaging) during the COVID-19 pandemic.
NICE signs agreement with Colombia’s Institute of Health Technology Assessment to forge closer working ties10/07/2020 14:05:00
Research and knowledge sharing key to collaborative working approach agreed the two agencies
NICE’s strategy on sustainability: current progress and next steps10/07/2020 09:15:00
Fizzah Ali, NICE clinical fellow, outlines the key steps towards a sustainability strategy at NICE.
Innovation through HTA: theme for HTAi 2021 Annual Meeting announced06/07/2020 13:43:00
Health Technology Assessment International (HTAi) has announced the theme for the 2021 Annual Meeting which will be held from 19-23 June in Manchester.
Cancer patients to benefit from new histology independent treatment26/06/2020 16:15:00
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
Steam treatment recommended for men with an enlarged prostate25/06/2020 16:15:00
Minimally invasive procedure involves injecting steam to destroy excess prostate tissue.
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis25/06/2020 13:43:00
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).